• HOME
  • ABOUT
  • NEWS
  • CONTACT US
  • HOME
  • ABOUT
  • NEWS
  • CONTACT US
  • CinDome
  • May 16, 2024
CinDome Pharma Announces $40 Million Series B Extension

CinDome Pharma Announces $40 Million Series B Extension

More

About Author

At Labstica, we believe in the power of collaboration, innovation, and continuous growth – both for our clients and ourselves.

  • LinkedIn
  • Instagram
  • Twitter
  • Facebook

Recent Post

CinDome Pharma Announces Completion of Enrollment in the envisionGI Phase 2 Study of Deudomperidone (CIN-102) for the Treatment of Idiopathic Gastroparesis
March 3, 2026
CinDome Pharma Announces Enrollment Completion in the envision3D Phase 2 Clinical Trial of Deudomperidone (CIN-102) for the Treatment of Diabetic Gastroparesis
September 9, 2025
CinDome Pharma Announces First Patient Dosed in Clinical Trial of Deudomperidone (CIN-102)
June 6, 2025

Tags

2023 Digestive Disease Week Conference Acquisition AstraZeneca Biotechnology Business Finance CIN-102 CIN-102 (deudomperidone) CinCor Pharma CinDome CinDome Pharma CinRx Pharma Deudomperidone Deuterated Domperidone Diabetic Gastroparesis envision Financing First Patient Dosed Funding Announcement Gastroparesis Healthcare Finance News Investment Pharmaceutical Funding Pharmaceutical Industry Phase 2 Clinical Trial Phase 2 Trial Poster presented Present a Poster Series B Extension vTv Therapeutics Inc.

844-531-1834 | info@cinrx.com

© 2025 CINRx Pharma. All Rights Reserved.

Site Pages

  • HOME
  • ABOUT
  • NEWS
  • CONTACT US
  • HOME
  • ABOUT
  • NEWS
  • CONTACT US

CINRx in The News

CinDome Pharma Announces Completion of Enrollment in the envisionGI Phase 2 Study of Deudomperidone (CIN-102) for the Treatment of Idiopathic Gastroparesis

March 17, 2026
Read More

CinDome Pharma Announces Enrollment Completion in the envision3D Phase 2 Clinical Trial of Deudomperidone (CIN-102) for the Treatment of Diabetic Gastroparesis

September 3, 2025
Read More

FOLLOW US

Linkedin-in

INVESTOR INQUIRIES

CinRx INQUIRIES